Cardiac natriuretic peptides: New laboratory parameters in heart failure patients

Clinical Laboratory

Volumn 47, Issue 5-6, 2001, Pages 265-277

  Hammerer Lercher, A ^a   Puschendorf, B ^a   Mair, J ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

ANP; BNP; Congestive heart failure; Diagnosis; Natriuretic peptides; Prohormone; Risk stratification

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; EDETIC ACID; HORMONE PRECURSOR;

ASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HEART FAILURE; HEART MUSCLE TENSION; HEART VENTRICLE OVERLOAD; HEART VOLUME; HUMAN; LABORATORY TEST; PARAMETER; PROGNOSIS; PROTEIN STABILITY; REVIEW; SENSITIVITY AND SPECIFICITY;

AGED; ANTICOAGULANTS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; CARDIAC OUTPUT, LOW; DRUG STABILITY; EDETIC ACID; FEMALE; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

EID: 0034997587     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Prevalence of heart failure and left ventricular dysfunction in the general population-The Rotterdam study
2. Consensus recommondations for the management of chronic heart failure
3. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction
4. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
5. A new natriuretic peptide in porcine brain
6. Cardiovascular and renal actions of C-type natriuretic peptide
7. Isolation and structural analysis of "urodilatin", a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
8. Contrasting cardiac regional responses of A-type and B-type natriuretic peptide to experimental chronic heart failure
9. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure
10. Regulation of gene expression in the endocrine heart
11. Cooperative interaction between GATA-4 and GATA-6 regulates myocardial gene expression
12. Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis
13. Developmental stage-specific regulation of atrial natriuretic factor gene transcription in cardiac cells
14. Circulating beta-atrial natriuretic factor in congestive heart failure in humans
15. Localization of the mosaic transmembrane serine protease corin to heart myocytes
16. Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme
17. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes
18. Natriuretic peptide system in human heart failure
19. Characterization of natriuretic peptide production by adult heart atria
20. Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans
21. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide
22. Cardiac fibrosis in mice lacking brain natriuretic peptide
23. Recent advances in ANF research
24. Natriuretic peptides in assessment of left-ventricular dysfunction
25. Structure of the dimerized hormone-binding domain of a guanylyl-cyclase-coupled receptor
26. Molecular biology of the natriuretic peptides and their receptors
27. Physiological role of silent receptors of atrial natriuretic factor
28. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
29. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure
30. Vasopeptidase inhibition: A new concept in blood pressure management
31. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial
32. Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts
33. Prolonged stability of brain natriuretic peptide: Importance for non-invasive assessment of cardiac function in clinical practice
34. Cardiac peptide stability, aprotinin and room temperature: Importance for assessing cardiac function in clinical practice
35. Plasma atrial natriuretic peptide is unstable under most storage conditions
36. In vitro stability of N-terminal proatrial natriuretic factor in unfrozen samples: An important prerequisite for its use as a biochemical marker of atrial pressure in clinical routine
37. Measurement of brain natriuretic peptide
38. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma
39. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-proBNP): A new marker of cardiac impairment
40. N-terminal proatrial natriuretic peptide and brain natriuretic peptide are stable for up to 6 hours in whole blood in vitro
41. Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: Implications for assessment of left ventricular dysfunction
42. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit
43. Pulsatile secretion of atrial natriuretic peptide and brain natriuretic peptide in healthy humans
44. 24-h variation in atrial natriuretic peptide
45. Variable patterns of atrial natriuretic peptide secretion in man
46. Is the secretion of atrial natriuretic peptide under neural control?
47. Measurement of brain natriuretic peptide in plasma samples and cardiac tissue extracts by means of an immunoradiometric assay method
48. Atrial natriuretic peptide: Synthesis, release, and metabolism
49. Release of atrial natriuretic peptide during pregnancy and immediate puerperium
50. Circulating levels of cardiac natriuretic peptides during menstrual cycle
51. Effect of haemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure
52. Stabilization of human brain natriuretic peptide in blood
53. Assay of brain natriuretic peptide (BNP) in human plasma: Evidence for high molecular weight BNP as a major plasma component in heart failure
54. Analytical performance and clinical usefulness of a commercially available IRMA kit for measuring atrial natriuretic peptide in patients with heart failure
55. Clinical evaluation of the Triage B-Type natriuretic peptide assay for point of care testing of patients with congestive heart failure
56. N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: Investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide natriuretic peptide (1-30) and atrial natriuretic peptide (99-126)
57. Enzyme immunoassay for fragments (epitopes) of human proatrial natriuretic peptides
58. Immunoradiometric assay for N-terminal fragment of proatrial natriuretic peptide (N-terminal proANP) in human plasma
59. Atrial natriuretic peptide elevation in congestive heart failure in humans
60. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure
61. Release of cyclic guanosine monophosphate evaluated as a diagnostic tool in cardiac disease
62. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy
63. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure - Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic dysfunction
64. N-terminal atrial natriuretic peptide and left ventricular geometry and function in a population sample of elderly males
65. Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction
66. Natriuretic peptides and cyclic guanosine 3',5'-monophosphate in asymptomatic and symptomatic left ventricular dysfunction
67. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
68. Biochemical detection of left-ventricular dysfunction
69. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin. New neurohormonal predictors of left ventricular function and prognosis after myocardial infarction
70. Plasma cardiac natriuretic peptide determination as a screening test for the detection of patients with mild left ventricular impairment
71. Sustained elevation of plasma brain natriuretic peptide levels associated with progressive ventricular remodelling after acute myocardial infarction
72. Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1
73. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure
74. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomised comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy
75. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations